When a patient is diagnosed with cancer today, a pathologist will look at a tumor sample and attempt to suggest the best treatment based on what they see in the microscope, which remains principally an analog technology. Augmentiqs is helping pathologists make more accurate interpretations and informed decisions for better patient outcomes by digitizing the microscope. Luminate Managing Director, Dr. Sujatha Ramanujan, sat down with clinical specialists at Augmentiqs, Marcus D’Aguiar and Brandon Buscaglia, to discuss how this startup is transforming the future of pathology. Hear how Augmentiqs is turning the microscope into a connected device, their thoughts on the exciting future of telepathology and 3D tumor modeling, and what it was like to participate in the second cohort of the Luminate accelerator.
Learn more about Augmentiqs at www.augmentiqs.com.
